Thyroid Nodules — When Should You Worry?

Thyroid nodules are surprisingly common — high-resolution ultrasound studies detect them in the majority of adults past a certain age, though they're far less often palpable on physical exam. Being told "you have a nodule on your thyroid," however, tends to trigger disproportionate anxiety, because in reality the vast majority of nodules are benign and never require treatment. We check what the American Thyroid Association guidelines and the TI-RADS system actually say about which nodules need further workup and which can safely be observed.

Redakcja VitMode — Hormony i endokrynologiathe VitMode editorial team, no individual bylinesPublishedSeptember 9, 202614 min readAbout 14 min left

How this article was made

Author: Redakcja VitMode — Hormony i endokrynologia — the VitMode editorial team, no individual bylines
Method: Prepared from primary sources: clinical trials, meta-analyses and guidelines. We describe study findings separately from our interpretation.
Source verification: Cited PubMed papers are automatically checked for a matching identifier, title and publication year.
Medical review: none — this article has not been reviewed by a physician
Last updated: September 9, 2026

The content is educational and does not replace medical advice. Read the full editorial process

Table of contents

TL;DR — key takeaways

→A common problem that rarely turns out to be dangerous
→Where thyroid nodules come from — the mechanism
→How risk is assessed on imaging — the TI-RADS system
→Sonographic features that genuinely raise suspicion
→Fine-needle biopsy and the Bethesda classification
→How many thyroid nodules are actually cancer
→The rise in thyroid cancer diagnoses — is this a real epidemic?
→Risk factors worth paying attention to
→Myth versus fact
→What not to do — myths about "treating" nodules
→What's worth doing in practice
→Limitations of this evidence
→Our editorial recommendation

A common problem that rarely turns out to be dangerous

A thyroid nodule is any circumscribed change in thyroid tissue that differs in structure from the surrounding parenchyma — it may be solitary or one of many within what's known as a multinodular goiter. Nodules are relatively rare to feel on physical examination, but when high-frequency ultrasound is used for evaluation, the picture changes drastically: population studies show that thyroid nodules can be detected in a substantial share, and in some studies even the majority, of adults examined, with frequency rising markedly with age.

Where thyroid nodules come from — the mechanism

The thyroid consists of millions of follicles that secrete hormones under the influence of TSH from the pituitary gland. Nodules form when certain areas of tissue begin to grow independently of the rest of the gland — most often as a result of benign proliferation of follicular cells (colloid adenoma, hyperplastic nodule), fluid accumulation in a post-follicular space (cyst), a chronic inflammatory process in the course of Hashimoto's disease (described in more detail in our article on hypothyroidism), or, less commonly, uncontrolled neoplastic growth.

Some nodules are so-called autonomous nodules — tissue that produces thyroid hormones independently of TSH regulation, which in larger sizes can lead to hyperthyroidism. Chronic iodine deficiency, or less commonly excess, also matters — a topic we discuss in more detail in another article — in regions with iodine deficiency, multinodular goiter is significantly more common, though in Poland, after the salt-iodization program, this factor is less significant today than several decades ago.

The key clinical question for any newly detected nodule, then, isn't "is this something," because a nodule is by definition already a visible, distinct lesion — it's: what is the probability that this particular lesion is malignant, and how can that probability best be estimated without subjecting every patient to unnecessary, invasive diagnostics.

How risk is assessed on imaging — the TI-RADS system

The answer to that question is a structured ultrasound assessment. For decades, different radiologists described thyroid nodules inconsistently, which made it difficult to compare results and make consistent biopsy decisions. In 2017, the American College of Radiology (ACR) published the TI-RADS (Thyroid Imaging Reporting and Data System), which standardized this assessment.

What does the research say?

ACR Thyroid Imaging, Reporting and Data System (TI-RADS): White Paper of the ACR TI-RADS Committee

Tessler FN, Middleton WD, Grant EG, Hoang JK, Berland LL, Teefey SA et al. · Journal of the American College of Radiology · 2017

Study findings

A point-based system assessing five categories of nodule features visible on ultrasound: composition (solid/mixed cystic-solid/spongiform), echogenicity, shape, margin, and the presence of echogenic foci (e.g., microcalcifications). The total score assigns the nodule to one of five risk categories (TR1-TR5), and the biopsy decision depends on the combination of category and nodule size. Compared with earlier, less structured systems, ACR TI-RADS reduces the number of unnecessary biopsies of benign nodules by 19.9-46.5%, while maintaining high sensitivity for detecting malignant lesions.

Strong evidenceView the study on PubMed

This describes what the study found. Editorial interpretation follows in the text below.

In practice, this means that an ultrasound report on a thyroid nodule today, at many centers, includes a specific TI-RADS category rather than just a descriptive "suspicious nodule" or "non-suspicious nodule." This is an important change — the biopsy decision no longer depends solely on the subjective impression of the person performing the exam, but on a standardized score that can be compared between centers.

Sonographic features that genuinely raise suspicion

An important caveat: no single feature is diagnostic on its own — that's exactly why the TI-RADS scoring system was created, combining several features at once, since a single feature assessed subjectively has limited predictive value. Large fluid-filled nodules (cysts) and spongiform-structured nodules (numerous small fluid-filled spaces), on the other hand, have very low malignancy risk regardless of size, which often allows biopsy to be avoided even for relatively large lesions.

Fine-needle biopsy and the Bethesda classification

When the sonographic features and size of a nodule indicate a need for further workup, the standard is ultrasound-guided fine-needle aspiration biopsy (FNA) — a short, outpatient procedure involving the collection of cellular material without the need for general anesthesia. The collected material is assessed using the Bethesda classification, a six-tier scale covering categories from "non-diagnostic" through "benign lesion," "atypia of undetermined significance," up to "suspicious for malignancy" and "malignant."

How many thyroid nodules are actually cancer

What does the research say?

2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer

Haugen BR, Alexander EK, Bible KC et al. (American Thyroid Association Guidelines Task Force) · Thyroid · 2016

Study findings

American Thyroid Association guidelines indicate that the proportion of thyroid nodules that turn out to be malignant after full workup is usually around 5-15% in the adult population — a higher proportion applies to children and adolescents and to people with a nodule after prior irradiation of the neck area. The guidelines introduced a five-tier sonographic risk classification with specific size thresholds for biopsy eligibility (from 10 mm for high-risk lesions to 20 mm or more for very-low-risk lesions), and for nodules with benign features and very low risk, they permit observation alone without biopsy.

Strong evidenceView the study on PubMed

This describes what the study found. Editorial interpretation follows in the text below.

The rise in thyroid cancer diagnoses — is this a real epidemic?

Since the 1980s, the number of thyroid cancer diagnoses has been rising steadily in many countries — in the United States, incidence has increased by as much as around 250% since 1990. At first glance, this looks like an alarming trend. Closer analysis shows something different, however: thyroid-cancer-related mortality has stayed practically unchanged over the same period, and the growing number of diagnoses concerns almost exclusively small, asymptomatic forms of papillary carcinoma (microcarcinoma, ≤1 cm), detected mainly incidentally during ultrasound performed for other reasons.

What does the research say?

Unravelling the rise in thyroid cancer incidence and addressing overdiagnosis

Chen DW, Haymart MR · Nature Reviews Endocrinology · 2026

Study findings

A review analyzing the causes of the global rise in thyroid cancer incidence. The authors indicate that the dominant factor is the wider availability and more frequent use of neck ultrasound (including incidental use, during imaging performed for other indications), leading to the detection of small, biologically inactive lesions that likely would never have become clinically significant had they not been found incidentally. Some independent analyses estimate that overdiagnosis may have accounted for as much as 72-94% of papillary carcinoma cases diagnosed in the US between 1991 and 2019.

Moderate evidenceView the study on PubMed

This describes what the study found. Editorial interpretation follows in the text below.

A consequence of this observation is a shift in the approach to small, low-risk papillary carcinomas (microcarcinoma). In Japan, as part of the Kuma Hospital protocol, research into active surveillance (observation without immediate surgery) of such lesions has been conducted since the 1990s.

Check your profile

Not sure which supplements actually make sense for you?

Answer a few short questions about your lifestyle, diet, sleep, and goals. VitMode will build your profile and show supplements worth considering — with reasoning and evidence strength.

Takes about 2 minutesBased on scientific evidence

Find supplements for me

Recommendations take your answers and the strength of the scientific evidence into account. A supplement's popularity has no bearing on whether it gets recommended.

Risk factors worth paying attention to

What you can do

What actually increases the risk that a nodule will turn out to be malignant

Prior exposure to head and neck irradiation, especially in childhood — risk rises with dose and is higher the younger the age at exposure
A positive family history of thyroid cancer, especially medullary thyroid carcinoma, which can be hereditary
Rapid growth of the nodule or new symptoms — hoarseness, difficulty swallowing, palpable enlarged cervical lymph nodes
A nodule in a child or young person — the malignancy rate in this age group is significantly higher than in adults
A nodule in a man — even though thyroid nodules as such are much more common in women, a detected nodule in a man statistically more often turns out to be malignant
A history of chronic Hashimoto's disease, which slightly increases the risk of certain thyroid cancer subtypes, though it is itself an autoimmune, not a neoplastic, disease

Myth versus fact

Myth

Detecting a thyroid nodule is an alarm signal — you need to worry it's cancer until that possibility is ruled out.

Fact

The vast majority of detected nodules — depending on the study, 90% or more — are benign. The TI-RADS system and ATA guidelines exist precisely to distinguish this majority, requiring only observation, from the minority requiring biopsy or further treatment — not to automatically classify every nodule as a potential threat.

The opposite extreme can be just as problematic: completely ignoring the information about a nodule, with no further evaluation at all, isn't a reasonable approach either — even a small malignancy percentage in a population where nodules are as common as thyroid nodules translates, in absolute numbers, into a real number of cases requiring treatment. A reasonable approach lies between panic and complete neglect: a structured ultrasound assessment and, where indicated, biopsy, without catastrophizing the mere fact that a lesion exists.

What not to do — myths about "treating" nodules

Limits and risks

Iodine supplementation, herbs, and TSH suppression aren't recognized treatments for nodules

Self-directed iodine supplementation to "shrink a nodule" without prior workup can be harmful — excess iodine can induce or unmask hyperthyroidism, especially in the presence of autonomous nodules. TSH-suppressive therapy (giving levothyroxine at doses that lower TSH below normal, aiming to inhibit nodule growth) was more widely used in the past, but current ATA guidelines don't recommend it routinely in adults with benign nodules, given the modest, uncertain benefit and the real risk of side effects from subclinical hyperthyroidism (including for the cardiovascular system and bone density) with long-term use. No herbs or supplements have solid evidence for shrinking thyroid nodules — decisions about any treatment (observation, levothyroxine therapy in selected cases, ablation, surgery) should be made by a physician based on a full workup.

If hypothyroidism from Hashimoto's disease coexists alongside a nodule, treatment with levothyroxine follows from the hypothyroidism itself (normalizing TSH), not from a desire to "treat" the nodule as such — an important clinical distinction that's easy to conflate when reading information online.

What's worth doing in practice

What you can do

Practical steps after a thyroid nodule is detected

Ask for a full ultrasound report with a specific risk category (e.g., TI-RADS TR1-TR5), not just a general "nodule visible" description
Ask your doctor about the recommended next step — observation with follow-up ultrasound after a set time, or biopsy — and about the reasoning for that decision based on size and sonographic features
Get a basic TSH test — an autonomous nodule with hyperthyroidism requires a different diagnostic approach than a nodule with normal thyroid function
If the biopsy result falls into an indeterminate category (Bethesda III-IV), ask about the availability of additional molecular testing, which in some cases can help avoid diagnostic surgery
Don't start self-directed supplementation with iodine, herbs, or other "natural" methods aimed at shrinking a nodule without prior consultation
If diagnosed with a small, low-risk microcarcinoma, ask whether active surveillance is a real, safe alternative to immediate surgery in your case

Limitations of this evidence

Question	Short answer
How common are thyroid nodules?	Very common on high-resolution ultrasound — as many as 68% of adults in one study
How many nodules are cancer?	Usually 5-15% of nodules given a full workup, according to ATA guidelines
Does every nodule need a biopsy?	No — the decision depends on the combination of size and TI-RADS risk category on ultrasound
Is the rising number of thyroid cancer diagnoses a real epidemic?	Partly not — largely a result of more frequent, including incidental, ultrasound use and detection of small, inactive lesions
Do supplements or herbs shrink nodules?	No solid evidence for this — treatment decisions require medical evaluation

Thyroid nodules at a glance

Our editorial recommendation

Thyroid nodules are a good example of how easily the mere frequency of detecting a medical phenomenon can be read as a rise in its danger, when in reality it mainly reflects the sensitivity of today's imaging diagnostics. Structured assessment systems like TI-RADS and evidence-based ATA guidelines now make it possible to distinguish nodules requiring further workup from those that can be safely observed — without needing to biopsy every detected lesion.

A reasonable approach to a newly detected thyroid nodule isn't to ignore it, but also not to catastrophize the mere fact of its existence. It's worth asking for the specific risk category in the ultrasound report, understanding the reasoning behind the recommended next step, and, if in doubt, seeking a second opinion — rather than looking for answers in supplements or diets with no confirmed effect on nodular tissue.

The mere presence of a thyroid nodule isn't a diagnosis — it's a starting point for a structured evaluation that, in most cases, ends with the conclusion: observe, don't operate.

VitMode editorial team

Frequently asked questions

No. The decision to biopsy depends on the combination of the nodule's size and its risk category in the TI-RADS system as assessed on ultrasound. Nodules with very low sonographic risk, especially smaller ones, often qualify only for observation with follow-up ultrasound, without the need for biopsy.

According to American Thyroid Association guidelines, in adults undergoing full workup, the malignancy rate is usually 5-15%. A higher rate applies to children, adolescents, and people with a nodule after prior irradiation of the neck area.

Not fully. Epidemiological analyses indicate that the rise in diagnoses largely results from more frequent neck ultrasound use and incidental detection of small, asymptomatic lesions, rather than a real increase in the number of aggressive cancers — thyroid-cancer-related mortality has remained largely stable over this period in most countries.

It's a strategy of observation without immediate surgery, used only for a strictly selected group — small, asymptomatic, low-risk papillary microcarcinomas. Studies from Japan show that most such patients don't experience significant growth of the lesion over years of follow-up. This is, however, a decision requiring individual medical evaluation, not a universal rule for every nodule.

There's no solid evidence for this, and self-directed iodine supplementation without prior workup can be risky — excess iodine can trigger or unmask hyperthyroidism, especially in the presence of autonomous nodules. Any decision about supplementation in the context of a nodule is worth discussing with a physician.

Current ATA guidelines don't recommend routine use of TSH-suppressive therapy in adults with benign thyroid nodules — the benefit is uncertain and modest, and long-term suppression of TSH carries a real risk for the cardiovascular system and bone density.

People with prior exposure to head and neck irradiation (especially in childhood), a positive family history of thyroid cancer, children and adolescents, men with a detected nodule, and people with a rapidly growing lesion, hoarseness, or enlarged cervical lymph nodes.

Sources (5)

Sources are numbered. PubMed items are automatically verified (identifier, title, year).

Redakcja VitMode — Hormony i endokrynologia

VitMode editorial team — no individual bylines; content based on primary sources

VitMode Editorial — Hormones and Endocrinology is the VitMode editorial team responsible for: hormones, testosterone therapy, the thyroid and metabolism. The team has no individual bylines — texts are prepared by VitMode editors from primary sources (clinical trials, meta-analyses, guidelines). Every cited PubMed paper is automatically checked for a matching identifier, title and publication year. The content is educational and does not replace medical advice. Factual errors can be reported in a comment under the post or through the contact form; corrections are made by the editorial team.